Over 200 New York Auctions End Today - Bid Now
Over 350 Total Lots Up For Auction at Four Locations - Over 100 Utah Auctions End Tomorrow 02/03 - Bid Now, MD 02/08, TX 02/10, Ontario 02/14

Latest tools in machine learning aim to accelerate precision medicine through American Heart Association and Duke Clinical Resea

Press releases may be edited for formatting or style | March 09, 2018 Artificial Intelligence Cardiology
DALLAS, March 9, 2018 – A new strategic alliance will target the prediction, prevention and treatment of cardiovascular diseases using artificial intelligence computing and big data, the American Heart Association (AHA) and the Duke Clinical Research Institute (DCRI) announced today.

The AHA’s Institute for Precision Cardiovascular MedicineTM together with the DCRI’s data science team, under the direction of Michael Pencina, Ph.D., and Lawrence Carin, Ph.D., will develop and test machine learning methods on the AHA Precision Medicine Platform, which is powered by Amazon Web Services.

“Together, we will develop new methods and technology for analyzing data, and create abundant opportunities for trainees to excel,” said Jennifer Hall, Ph.D., chief of the AHA’s Institute for Precision Cardiovascular Medicine. “We’re pleased to work with the DCRI’s team of data science experts to develop and test emerging strategies to power machine learning.”

Machine learning, a type of artificial intelligence, refers to methods that use complex mathematical algorithms that are “trained” and optimized on large amounts of data. These methods can be especially useful for problems with large amounts of data with many variables. Machine learning can enhance how massive volumes of datasets are labeled and annotated to improve researchers’ understanding of deep learning methods.

The strategic alliance will investigate how big data is managed, accessed, harmonized, searched and deposited, specific to secondary analyses of clinical databases. In addition, DCRI and AHA will leverage their grants for big data harmonization and methods to create novel machine learning tools and aggregated data repositories.

“There is great potential in machine learning and other artificial intelligence methods to discover new insights, but we have to be sensible and think clearly about how we use it,” said Pencina, the DCRI’s director of biostatistics and a professor of biostatistics and bioinformatics at the Duke School of Medicine. “I think team science is the key that unlocks that potential.”

The DCRI’s more than 1,300 staff members include 76 clinicians from the Duke School of Medicine and more than 100 biostatisticians and data scientists. Both sets of experts, in conjunction with the powerful technology established by the AHA’s Institute for Precision Cardiovascular Medicine, offer an ideal alliance for unlocking the potential of artificial intelligence to address the challenges of preventing and treating cardiovascular disease.

You Must Be Logged In To Post A Comment